Drug intelligence / Profile preview

NWRD09

Development stage: Phase 2
Lead developer: Newish Technology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

NWRD09 is an investigational HPV-16 targeted mRNA vaccine developed by Newish Technology (Beijing) for the treatment of cervical cancer and HPV-16 related intraepithelial neoplasias. It is designed to induce an immune response against cells expressing the HPV-16 antigen, aiming to treat or prevent progression of cervical, vaginal, and vulvar pre-cancerous lesions as well as cervical cancer. The vaccine is administered via intramuscular injection and is currently being evaluated in Phase 1 clinical trials for safety and efficacy in patients with HPV-16 positive or related diseases[1][2][3][4][5][6][7].

Targets

HPV16 L2

Beyond the preview

Go deeper on NWRD09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NWRD09.

Explore the full profile